Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Myeloma Center
Explore this Website
Home
About Us
Toggle About Us menu options
Our Team
For Patients
Toggle For Patients menu options
About Multiple Myeloma, Amyloidosis, and Other Plasma Cell Disorders
Multiple Myeloma
Amyloidosis
Other Plasma Cell Disorders
Toggle Other Plasma Cell Disorders menu options
Precursor Conditions to Multiple Myeloma
Myeloma Signs and Symptoms
Amyloidosis Signs and Symptoms
Risk Factors for Multiple Myeloma and Other Plasma Cell Disorders
Diagnosing Multiple Myeloma and Other Plasma Cell Disorders
Multiple Myeloma and Plasma Cell Disorder Treatment
Understanding and Managing Side Effects
Your First Visit
Toggle Your First Visit menu options
Self-Referral
Support Groups and Helpful Links
Frequently Asked Questions
Referring Physicians
Toggle Referring Physicians menu options
Refer a Patient
Research and Clinical Trials
Toggle Research and Clinical Trials menu options
Basic and Translational Research
Bibliography
Contact Us
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
For Patients
Referring Physicians
Research and Clinical Trials
Contact Us
Home
Bibliography
Bibliography
Basic and Translational Research
Bibliography
Bibliography
Found 11 results
Author
[
Title
]
Type
Year
Filters:
Keyword
is
Recurrence
[Clear All Filters]
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
C
A Stewart K
,
S Rajkumar V
,
Dimopoulos MA
,
Masszi T
,
Spicka I
,
Oriol A
,
Hajek R
,
Rosiñol L
,
Siegel DS
,
Mihaylov GG
et al.
. 2015.
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
.
N Engl J Med. 372(2):142-52.
Dimopoulos MA
,
A Stewart K
,
Masszi T
,
Spicka I
,
Oriol A
,
Hajek R
,
Rosiñol L
,
Siegel D
,
Mihaylov GG
,
Goranova-Marinova V
et al.
. 2017.
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.
.
Br J Haematol. 177(3):404-413.
Avet-Loiseau H
,
Fonseca R
,
Siegel D
,
Dimopoulos MA
,
Spicka I
,
Masszi T
,
Hajek R
,
Rosiñol L
,
Goranova-Marinova V
,
Mihaylov G
et al.
. 2016.
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.
.
Blood. 128(9):1174-80.
van Besien K
,
Koshy N
,
Gergis U
,
Mayer S
,
Cushing M
,
Rennert H
,
Reich-Slotky R
,
Mark T
,
Pearse R
,
Rossi A
et al.
. 2017.
Cord blood chimerism and relapse after haplo-cord transplantation.
.
Leuk Lymphoma. 58(2):288-297.
E
Rosenbaum C
,
Jasielec J
,
Laubach J
,
Prada CPaba
,
Richardson P
,
Jakubowiak AJ
. 2013.
Evolving strategies in the initial treatment of multiple myeloma.
.
Semin Oncol. 40(5):592-601.
H
A Stewart K
,
Dimopoulos MA
,
Masszi T
,
Spicka I
,
Oriol A
,
Hajek R
,
Rosiñol L
,
Siegel DS
,
Niesvizky R
,
Jakubowiak AJ
et al.
. 2016.
Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.
.
J Clin Oncol. 34(32):3921-3930.
I
Moreau P
,
Joshua D
,
Chng W-J
,
Palumbo A
,
Goldschmidt H
,
Hájek R
,
Facon T
,
Ludwig H
,
Pour L
,
Niesvizky R
et al.
. 2017.
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study.
.
Leukemia. 31(1):115-122.
P
Niesvizky R
,
Badros AZ
,
Costa LJ
,
Ely SA
,
Singhal SB
,
Stadtmauer EA
,
Haideri NA
,
Yacoub A
,
Hess G
,
Lentzsch S
et al.
. 2015.
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
.
Leuk Lymphoma. 56(12):3320-8.
Kaufman JL
,
Niesvizky R
,
Stadtmauer EA
,
Chanan-Khan A
,
Siegel D
,
Horne H
,
Wegener WA
,
Goldenberg DM
. 2013.
Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma.
.
Br J Haematol. 163(4):478-86.
Mark TM
,
Coleman M
,
Niesvizky R
. 2014.
Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma.
.
Leuk Res. 38(5):517-24.
S
Vij R
,
Wang M
,
Jagannath S
,
Niesvizky R
,
Jakubowiak AJ
,
Kavalerchik E
,
Huang M
,
Siegel DS
. 2015.
Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.
.
Leuk Lymphoma. 56(10):2959-61.